Changes in the arrhythmic profile of patients treated for heart failure are associated with modifications in their myocardial perfusion conditions

Cardiology Journal

Volumn 15, Issue 3, 2008, Pages 261-267

  Asensio Lafuente, Enrique ^a   Castillo Martínez, Lilia ^a   Orea Tejeda, Arturo ^a   Silva Tinoco, Rubén ^a   Dorantes García, Joel ^a   Narváez David, René ^a   Rebollar González, Verónica ^a  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

Arrhythmias; Heart failure; Holter; Risk stratification; Scintigraphy

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; DIURETIC AGENT; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENDOTHELIAL DYSFUNCTION; FEMALE; FOLLOW UP; HEART ARRHYTHMIA; HEART FAILURE; HEART MUSCLE ISCHEMIA; HEART MUSCLE NECROSIS; HEART MUSCLE PERFUSION; HEART RATE VARIABILITY; HEART SCINTISCANNING; HEART VENTRICLE EXTRASYSTOLE; HOLTER MONITORING; HUMAN; MAJOR CLINICAL STUDY; MALE; MYOCARDIAL HIBERNATION; OBSERVATIONAL STUDY; OUTPATIENT DEPARTMENT; PATIENT SELECTION; PROSPECTIVE STUDY; CORONARY ARTERY BLOOD FLOW; DRUG EFFECT; ELECTROCARDIOGRAPHY; MIDDLE AGED; PATHOPHYSIOLOGY; RISK ASSESSMENT; SCINTISCANNING;

AGED; ARRHYTHMIAS, CARDIAC; CORONARY CIRCULATION; ELECTROCARDIOGRAPHY, AMBULATORY; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RADIONUCLIDE IMAGING; RISK ASSESSMENT;

EID: 54049099669     PISSN: 18975593     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Hunt SA, Abraham WT, Chin MH et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation, 2005; 112: 154-235.
2. Medscape Cardiology 2004 (http://www.medscape.com/viewarticle/466090_1).
3. De Teresa E, Alzueta J, Jiménez M. Profiling risk from arrhythmic or hemodynamic death. Am J Cardiol, 198; suppl. K: 126K-132K.
4. Asensio E, Narváez R, Dorantes J et al. Conceptos actuales sobre la muerte bita. Gac Med Mex, 2005; 141: 89-98.
5. Ferrara R, Mastrorilli F, Pasanisi G et al. Neurohormonal modulation in chronic heart failure. Eur Heart J, 2002; 4 (suppl. D): D3-D11.
6. Haq S, Choukroun G, Lim H et al. Differential activation of signal transduction pathways in human hearts with hypertrophy versus advanced heart failure. Circulation, 2001; 103: 670-677.
7. Weber K. Aldosterone in congestive heart failure. N Engl J Med, 2001; 345: 1689-1689.
8. Mann D, Spinale F. Activation of matrix metalloproteinases in the failing human heart. Breaking the tie that binds. Circulation, 1998; 98: 1699-1702.
9. Deedwania P. Ventricular arrhythmias and sudden death in heart failure: Evaluation and management. 20th Annual scientific sessions of the North American Society of Pacing and electrophysiology 1999 (http://www.medscape.com/medscape/cno/1999/NASPE/Story.cm?story_id-585).
10. Nolan J, Batin P, Andrews R et al. Prospective study of heart rate variability and mortality in chronic heart failure. Results of the United Kingdom Heart failure evaluation and assessment of risk trial (UK-Heart). Circulation, 1998; 98: 1510-1516.
11. Kleiger R, Stein P. Heart rate variability. In: Malik M ed. Risk of arrhythmia and sudden death. BMJ Books, London 2001: 221-234.
12. Church T. Risk assessment and risk stratification in sudden cardiac death: A biostatistician's view. Pacing Clin Electrophisiol, 1997; 20 (19 Part 2): 2520-2532.
13. Madsen B, Rasmussen V, Hansen J. Predictors of sudden death and death from heart failure in patients with heart insufficiency are different. Ugeskr Laeger, 1999; 161: 34-39 (Medline Abstract).
14. Green M, Ricci J, Wolfe K. The appropriate evaluation of the patient at risk for sudden death from ventricular arrhythmias. Can J Cardiol, 2000; 16 (suppl. C): 13C-15C.
15. The CAST investigators: Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Eng J Med, 1989; 321: 406-412.
16. Myerburg R, Interian A, Mitrani R, Kessler K, Castellanos A. Frequency of sudden cardiac death and profiles of risk. Am J Cardiol, 1997; 80 (5B): 10F-19F.
17. Leier C, Alvarez R, Binkley J. The problem of ventricular dysrhythmias and sudden death mortality in heart failure: The impact of current therapy. Cardiology, 2000; 93 (1-2): 56-69.
18. Teerlink J, Jalaludin M, Anderson S et al. Ambulatory ventricular arrhythmias in patients with heart failure do not specifically predict an increased risk of sudden death. PROMISE (Prospective Randomized Milrinone Survival Evaluation) investigators. Circulation, 2000; 101: 40-46.
19. Cárdenas E, Asensio E, Orea A et al. Impacto de la terapia médica en las arritmias y variabilidad de la frecuencia cardiaca detectadas por holter de 24 horas en una serie de pacientes de una clínica de insuficiencia cardiaca. Rev Invest Clin, 2004; 56: 609-614.
20. Orea-Tejeda A, Castillo-Martinez L, Aguilar-Sáenz C et al. Reverse redistribution phenomenon in patients with normal coronary epicardial arteries and its relationship to systolic left ventricular dysfunction. Intern J Cardiol, 2007; 4: 1.
21. St John M, Lee D, Rouleau J, Goldman S, Plappert T, Braunwald E, Pfeffer M. Left ventricular remodeling and ventricular arrhythmias after myocardial infarction. Circulation, 2003; 107: 2577-2582.
22. Ebinger M, Krishnan S, Schuger C. Mechanisms of ventricular arrhythmias in heart failure. Curr Heart Fail Rep, 2005; 2: 111-117.
23. Ellison K, Stevenson W, Sweeney M, Epstein L, Maisel W. Management of arrhythmias in heart failure. Congest Heart Fail, 2003; 9: 91-99.
24. Chan P, Hayward R. Mortality reduction by implantable cardioverter-defibrillators in high-risk patients with heart failure, ischemic heart disease, and new onset ventricular arrhythmias: An effectiveness study. J Am Coll Cardiol, 2005; 45: 1474-14781.
25. Eckardt L, Heverkamp W, Breithardt G. Antiarrhythmic therapy in heart failure. Heart Fail Monit, 2002; 2: 110-119.
26. Mecca A, Barakat T, Guo H, Olshansky B. Implantable cardioverter defibrillator therapy for patients with life-threatening ventricular arrhythmias and severe heart failure. Am J Cardiol, 2000; 86: 875-877.
27. Bedi M, Postava L, Murali S et al. Interaction of implantable defibrillator therapy with angiotensin-converting enzyme deletion/ insertion polymorphism. J Cardiovasc Electrophysiol, 2004; 15: 1162-1166.
28. Goldenberg I, Moss A, McNitt S, Zareba W, Hall W, Andrews M. Inverse relationship of blood pressure levels to sudden cardiac mortality and benefit of the implantable cardioverter-defibrillator in patients with ischemic left ventricular dysfunction. J Am Coll Cardiol, 2007; 49: 1427-1433.
29. Goldenberg I, Moss A, Hall et al. Causes and consequences of heart failure after prophylactic implantation of a defibrillator in the multicenter automatic defibrillator implantation trial II. Circulation, 2006; 113: 2810-2817.
30. Epstein A, Bigger T, Wyse G, Romhilt W, Reynolds A, Hallstrom P. Events in the Cardiac Arrhythmia Suppression Trial (CAST): Mortality in the entire population enrolled. J Am Coll Cardiol, 1991; 18: 14-19.
31. McMurray J. Beta-blockers, ventricular arrhythmias and sudden death in Heart failure: Not as simple as it seems. Eur Heart J, 2000; 21: 1214-1215.